Journal Club 2011


 PDF-Link for institution's members only (password required, see infoboard of UVCM, Inselspital)

12-28-2011

Thalidomide in bleeding vascular malformations:

CT Colonoscopy as a triage tool after positive fecal blood tests:


11-30-2011

Switching from Infliximab to Adalimumab: is it save?


  • Van Assche G et al.: Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2011 [ahead of print].http://www.ncbi.nlm.nih.gov/pubmed/21948942

Proton pump Inhibitors, do they affect the Efficaty of Aspirin:

  • 
Charlot M et al.: Protonpumpinhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011 [ahead of print]
 http://www.ncbi.nlm.nih.gov/pubmed/21562004

11-16-2011

Aspirin lowers risk of colorectal cancer in patients with lynch syndrome
:

  • Burn J et al.: Long-term eff ect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, Published Online October 28. http://www.ncbi.nlm.nih.gov/pubmed/22036019

High Fiber Diet Does Not Protect Against Asymptomatic Diverticulosis:


10-19-2011

Adenocarcinoma among Patients with Barrett’s Esophagus:

Rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection:

  • 
Garey KW et al.: A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011 Sep 21. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/21948965

09-21-2011

Early versus Late Parenteral Nutrition in Critically Ill:

Dextranomer to Treat Faecal incontinence

  • Graf et al.: Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet 2011; 377:997–1003.http://www.ncbi.nlm.nih.gov/pubmed/21420555

07-27-2011

Adalimumab for induction of remission in active ulcerative colitis

  • 
Reinisch W et al.: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-87.http://www.ncbi.nlm.nih.gov/pubmed/21209123

Predictors for Neoplastic Progression in Barrett's Esophagus:

  •  
  •  
  •  
  •  
© 2012-2015 Gastroenterology & Mucosal Immunology, Bern, Switzerland
Swiss Web Design